A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 40, Issue 2, 2007, Pages 157-163

  Slavin, M A ^a   Grigg, A P ^a   Schwarer, A P ^b   Szer, J ^a   Spencer, A ^b   Sainani, A ^a   Thursky, K A ^a   Roberts, A W ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; CEFEPIME; CYCLOSPORIN; FLUCONAZOLE; GENTAMICIN; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; PREDNISOLONE; VANCOMYCIN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG USE; EMPIRICISM; ENGRAFTMENT; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INTERMETHOD COMPARISON; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; MYELOABLATIVE CONDITIONING; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SEPSIS; WHOLE BODY RADIATION;

ADULT; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL INFECTIONS; CEPHALOSPORINS; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; NEUTROPENIA; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 34447250608     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705686     Document Type: Article

References (20)

1. Petersen F, Thornquist M, Buckner C, Counts G, Nelson N, Meyers J et al. The effects of infection prevention regimens on early infectious complications in marrow transplant patients: A four arm randomized study. Infection 1988; 16: 199-208.
2. Roberts AW, Grigg AP, de Boer R, Panuncialman G, Brown G, Street A et al. A pilot study of prophylactic intravenous antibodies to prevent fever and infection during allogeneic bone marrow transplantation. ANZ J Med 1993; 23: 141.
3. Avril M, Hartmann O, Valteau-Couanet D, Brugieres L, Kalifa C, Lemerle J. Antiinfective prophylaxis with ceftazidime and teicoplanin in children undergoing high-dose chemotherapy and bone marrow transplantation. Pediatr Hematol Oncol 1994; 11: 63-73.
4. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
5. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-3051.
6. Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25: 247-259.
7. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353: 977-987.
8. Baden LR. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 2005; 353: 1052-1054.
9. Carratala J, Alcaide F, Fernandez-Sevilla A, Corbella X, Linares J, Gudiol F. Bacteremia due to viridans streptococci that are highly resistant to penicillin: Increase among neutropenic patients with cancer. Clin Infect Dis 1995; 20: 1169-1173.
10. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995; 20: 557-560, discussion 561-563.
11. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994; 38: 681-687.
12. Bodey GP, Rodriguez V, Chang HY, Narboni G. Fever and infection in leukemic patients: A study of 494 consecutive patients. Cancer 1978; 41: 1610-1622.
13. Perez-Simon JA, Garcia-Escobar I, Martinez J, Vazquez L, Caballero D, Canizo C et al. Antibiotic prophylaxis with meropenem after allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 33: 183-187.
14. Solano C, Gutierrez A, Martinez F, Gimeno C, Gomez C, Munoz I et al. Prophylaxis of early bacterial infections after autologous peripheral blood stem cell transplantation (PBSCT): A matched-pair study comparing oral fluoroquinolones and intravenous piperacillin-tazobactam. Bone Marrow Transplant 2005; 36: 59-65.
15. Shryock TR, Apley M, Jones RN, Lein DH, Thornsberry C, Walker RD et al. (eds). Institute, C.a.L.S. M31-A2 (Electronic Document) Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria 2002. Clinical and Laboratory Standards Institute: Wayne, Pennsylvania, USA.
16. Sorror ML, Leisenring W, Deeg HJ, Martin PJ, Storb R. Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Biol Blood Marrow Transplant 2005; 11: 814-815.
17. Gardner W, Mulvey EP, Shaw EC. Regression analyses of counts and rates: Poisson, overdispersed Poisson, and negative binomial models. Psychol Bull 1995; 118: 392-404.
18. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-693.
19. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29: 1402-1407.
20. Paul M, Yahav D, Fraser A, Leibovici L. Empirical antibiotic monotherapy for febrile neutropenia: Systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2006; 57 176-189.